Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Ciba-Geigy reveals renin inhibitors

May 10, 1996

P&U reports most potent K(ATP)-channel blocker yet discovered

May 10, 1996

Mavik aproved for marketing in U.S.

May 10, 1996

RS-66252 selective for AT1 receptors in vitro

May 10, 1996

Antihypertensive activity reported for FR-149581

May 10, 1996

E. Merck continues to investigate angiotensin II blockers

May 10, 1996

Servier develops S-18149 as putative venotropic agent

May 3, 1996

CPC-111 enters phase II for angioplasty indication

May 3, 1996

Nasal propranolol claimed by RiboGene for angina Rx

May 3, 1996

Novel PAI-1 inhibitor protects against vascular lesions

May 3, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...